BRIEF-TiGenix says no serious adverse events reported from sepsis challenge trial
March 12 (Reuters) - TiGenix Nv
* TiGenix completes treatment in phase I sepsis challenge trial with CX611
* Biological effect and safety results to be released 2nd quarter of 2015
* No serious adverse events have been reported Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.